Haemophilia 2002: Emerging risks of treatment

Haemophilia

Volumn 8, Issue 3, 2002, Pages 221-229

  Evatt, B L ^a   Farrugia, A ^b   Shapiro, A D ^b   Wilde, J T ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NONE

Author keywords

Haemophilia; Risks; Treatment

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; BLOOD CLOTTING FACTOR; CYTOCHROME P450; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; BIOTECHNOLOGY; BLEEDING; BLOOD COMPONENT THERAPY; CAREGIVER; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC PROCEDURE; DISEASE TRANSMISSION; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH CARE MANAGEMENT; HEMATOTHORAX; HEMATURIA; HEMOPHILIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TOLERANCE; INDWELLING CATHETER; INFECTION; INFECTION RISK; MORBIDITY; MORTALITY; PLASMA; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; SCREENING TEST; THROMBOSIS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; HEMOPHILIA A; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CATHETERS, INDWELLING; CREUTZFELDT-JAKOB SYNDROME; HEMOPHILIA A; HEMORRHAGE; HUMANS; PROTEASE INHIBITORS; RISK ASSESSMENT;

EID: 0036588823     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00612.x     Document Type: Article

References (53)

1. Soucie JM, Richardson LC, Evatt BE et al. Risk factors for infection with HBV and HCV in a large cohort of hemophiliac males. Transfusion 2001; 41: 338-43.
2. World Federation of Hemophilia. Report on the WFH Global Survey 2000 Montreal, Canada, July 2000.
3. World Federation of Hemophilia. Report on the WFH Global Survey 2001 Montreal, Canada, July 2001.
4. Prusiner SB, Prions. Proc Natl Acad Sci 1998; 95: 13363-83.
5. Ricketts MN, Cashman NR et al. Is Creuzfeldt-Jakob disease transmitted in blood? Emerging Inf Dis 1997; 00: 3155-63.
6. European Commission. Communication from the Commission on the Precautionary Principle URL: http://europa.eu.int/comm/dgs/health_consumer/library/pub/pub07.pdf, 2000.
7. Menache D, O'Malley JP. Creuzfeldt-Jakob disease: current US policy to further reduce the possible risk of transmission by transfusion. Biologicals 1996; 24: 277-83.
8. Wilson K, Code C, Ricketts M. Risk of acquiring Creuzfeldt-Jakob disease from blood transfusions. Systematic review of case-controlled studies. Br Med J 2000; 321: 17-9.
9. Center for Biologics Evaluation and Research. Change to the Guidance Entitled Revised Precautionary Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) by Blood and Blood Products. URL: http://www.fda.gov/cber/infosheets/cjdchange.htm, 1998.
10. Will RG, Ironside JW et al. A new variant of Creuzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-5.
11. Scott MR, Will R et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy to humans. Proc Natl Acad Sci 1999; 96: 15137-42.
12. Hill AF, Zeidler M et al. Diagnosis of new variant Creuzfeldt-Jakob disease by tonsil biopsy. Lancet 1997; 349: 99-100.
13. Taylor DM, Fernie K, Reichl HE, Somerville RA. Infectivity in the blood of mice with a BSE-derived agent. J Hosp Infect 2000; 46: 78-9.
14. Houston F, Foster JD, Ching A, Hunter N, Bostock CJ. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356: 999-1000.
15. Baron H. Theoretical risk of CJD transmission through blood or blood products B what is known and what is needed? Presented at: Prions: Assessment and Management of Risks from Blood-borne TSE Infectivity. IBC USA Conferences Inc., 2001.
16. Centre for Biologics Evalution and Research. Revised Precautionary Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and New Variant Creutzfeldt-Jakob Disease (nvCJD) by Blood and Blood Products. URL: http://www.fda.gov/cber/gdlns/cjdnvcjd.pdf, 1999.
17. Brown P, Cervenakova L et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169-78.
18. Hill AF, Joiner S et al. Species barrier-independent prion replication in apparently resistant species. Proc Natl Acad Sci 2000; 97: 10248-53.
19. Brown P, Cervenakova L, Diringer H. Blood infectivity and the prospects for a diagnostic screening test in Creuzfeldt-Jakob disease, 2001.
20. MacGregor I. Prion protein and developments in its detection. Transfusion Med 2001; 11: 3-14.
21. Schmerr MJ, Jenny A et al. Use of capillary electrophoresis and fluorescent labelled peptides to detect the abnormal prion protein in the blood of animals that are infected with a transmissible spongiform encephalopathy. J Chromatogr A 1999; 853: 207-14.
22. Safar J, Wille H et al. Eight prion strains have PrPSc molecules with different conformations. Nature Med 1998; 4: 1157-65.
23. MacGregor I, Hope J et al. Application of a time-resolved fluorimmunoassay for the analysis of normal prion protein in human blood and its components. Vox Sanguinis 1999; 77: 88-96.
24. Dodd R. Comment during public meeting 'Can the public health service bovine spongiform encephalopathy/ transmissible spongiform encephalopathy (BSE/TSE) action plan be expanded to capitalize on the human and physical resources of the pharmaceutical and biotechnology industries?' URL: http://www.hhs.gov/bloodsafety/transcripts/20010924.html, 2001.
25. Taylor DM. Inactivation of prions by physical and chemical means. J Hosp Infect 1999; 43 (Suppl.): 569-76.
26. Lee DC, Stenland CJ et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001; 41: 449-55.
27. Petteway S. Partitioning of transmissible spongiform encephalopathy (TSE) by plasma or biotechnology manufacturing processes. Presented at The Policies and Science of Prions and Plasma workshop. Washington DC, 23-24 October 2001.
28. C, Rothschild M, Alcalay L. Macchi et al. Factor VIII SD-35-15: efficacy and safety clinical data with solvent-detergent treated and 35-15 nm filtered factor VIII concentrate. Thromb Haemost 2001; 46 (2): Abstract 2871.
29. Ljung RL, Petrini P, Lindgren A-K, Berntorp E. Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia. Acta Paediatr 1992; 81: 918-20.
30. Perkins JL, Johnson VA, Osip JM et al. The use of implantable venous access devices (IVADs) in children with hemophilia. J Ped Heme/Oncol 1997; 19 (4): 339-44.
31. Wurzel CL, Halom K, Feldman JG, Rubin LG. Infection rates of Broviac-Hickman catheters and implantable venous devices. AJDC 1998; 142: 536-40.
32. Blanchette VS, Abdulrahman AM, Stain AM, Ingram J, Fille RM. Central venous access devices in children with hemophilia: an update. Blood Coagul Fibrinol 1997; 8 (Suppl. 1): S11-14.
33. Medeiros D, Miller KL, Rollins NK, Buchanan GR. Contrast venography in young hemophiliacs with implantable central venous access devices. Haemophilia 1998; 4: 10-5.
34. Ljung R, van den Berg M, Petrini P et al. Port-A-Cath usage in children with haemophilia. experience of 53 cases. Acta Paediatr 1998; 87: 1051-4.
35. Ragni MV, Hord JD, Blatt J. Central venous catheter infection in haemophiliacs undergoing prophylaxis or immune tolerance with clotting factor concentrate. Haemophilia 1997; 3: 90-5.
36. Santagostino E, Gringeri A, Muca-Perja M, Mannucci PM. A prospective clinical trial of implantable central venous access in children with haemophilia. Br J Haematol 1998; 102 (5): 1224-8.
37. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98 (6); 1727-31.
38. Miller K, Buchanan GR, Zappa S et al. Implantable venous access devices in children with hemophilia: a report of low infection rates. J Pediatr 1998; 132 (6): 934-8.
39. WHO. WHO Drug Information 1996; 10 (3): 135.
40. Helal A. HIV protease inhibitors and increased bleeding in haemophilia? Can Med Assoc J 1997; 156: 90.
41. Ginsburg C, Salmon-Ceron D, Vassilief D et al. Unusual occurrence of spontaneous haematomas in three asymptomatic HIV-infected haemophilia patients a few days after the onset of ritonavir treatment. AIDS 1997; 11: 388-9.
42. Pollmann H, Richter H, Jurgens H. Platelet dysfunction as the cause of spontaneous bleeding in two haemophlic patients taking HIV protease inhibitors. Thromb Haemost 1998; 79: 1213-4.
43. Mandalaki T, Katsarou O, Panagiotopoulou C, Karafoulidou. Does protease inhibitor treatment induce increased bleeding tendency in haemophilia? Haemophilia 1998; 4: 766-8.
44. Perez R, Martinez ML, Cisneros IM, Sosa R. Incidence of increased number of bleeding episodes in HIV positive haemophiliacs treated with protease inhibitors. Haemophilia 1998; 4: 276.
45. Yee TT, Amrolia PJ, Lee CA, Mir N, Giangrande PL. Protease inhibitors and unusual bleeding in haemophiliacs. Haemophilia 1997; 3: 220-1.
46. Stanworth SJ, Bolton MJ, Hay CRM, Shiach CR. Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors. Haemophilia 1998; 4: 109-14.
47. Racoosin JA, Kessler CM. Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series. Haemophilia 1999; 5: 266-9.
48. Wilde JT, Lee CA, Collins P, Giangrande PLF, Winter M, Shiach CR. Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders. Br J Haematol 1999; 107: 556-9.
49. Merry C, McMahon C, Ryan M, O'Shea EO, Mulcahy F, Smith OP. Successful use of protease inhibitors in HIV-infected haemophilic patients. Br J Haematol 1998; 101: 475-7.
50. Capdevila JH, Falck JR, Estabrook RW. Cytochrome P450 and the arachidonate cascade. FASEB J, 1992; 6: 731-6.
51. Alvarez MT, Canales M, Villar A et al. Thrombopathy secondary to indinavir therapy in haemophiliac patients with HIV infection. Haemophilia 1998; 4: 276.
52. Carr A, Samaras K, Chisholm DJ. Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998; 352: 1881-3.
53. Herz J. The LDL-receptor-related protein B portrait of a multifunctional receptor. Curr Opin Lipidol 1993; 4: 107-13.